FOCL.US EDAP TMS S.A.
- Market cap
- USD 153M
- P/E
- -
- P/B
- 4.53x
- ROE
- -104.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is FOCL.US undervalued?
Graham numberThe Graham number of EDAP TMS S.A. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
EDAP TMS S.A. fundamental analysis
No fundamental analysis for EDAP TMS S.A. yet.
EDAP TMS S.A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About EDAP TMS S.A.
EDAP TMS S.A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. It also offers Focal One, a HIFU robotic system to treat patients diagnosed wit…
Full company profileEDAP TMS S.A. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
EDAP TMS S.A. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 39.4M | 40.3M | 46.2M | 50.3M | 47.5M | 52.1M | 57.9M | 65.3M | 69.4M | 70.7M | 54.5M |
| Gross Profit | 18.2M | 16.7M | 20.0M | 23.5M | 21.0M | 21.8M | 25.4M | 26.4M | 28.7M | 30.1M | 27.4M |
| Operating Income | 433K | -2.29M | -2.36M | 1.35M | -464K | -3.51M | -5.35M | -22.1M | -23.0M | -25.2M | -30.9M |
| EBITDA | 1.57M | -512K | -617K | 3.67M | 2.05M | 2.66M | -915K | -20.3M | -17.7M | -25.0M | -29.5M |
| Net Income | 4.25M | -768K | -399K | 1.69M | -1.94M | 827K | -3.08M | -22.9M | -20.6M | -29.3M | -37.4M |
| EPS | 0.14 | -0.03 | -0.01 | 0.06 | -0.07 | 0.03 | -0.09 | -0.62 | -0.55 | -0.78 | -0.88 |
| Balance Sheet | |||||||||||
| Total Assets | 49.1M | 56.3M | 55.7M | 59.6M | 67.5M | 87.8M | 108M | 101M | 89.1M | 79.0M | 111M |
| Total Liabilities | 23.1M | 24.9M | 26.0M | 27.7M | 34.1M | 30.9M | 31.5M | 38.2M | 46.8M | 59.6M | 74.8M |
| Shareholders' Equity | 25.8M | 30.2M | 28.5M | 30.7M | 32.1M | 56.9M | 76.4M | 62.9M | 42.3M | 19.4M | 35.9M |
| Cash & Short-term Investments | 23.2M | 24.0M | 22.3M | 23.4M | 30.2M | 53.7M | 67.4M | 48.0M | 30.9M | 20.5M | 56.3M |
| Total Debt | 2.91M | 5.67M | 7.71M | 9.72M | 13.6M | 11.4M | 10.0M | 9.37M | 14.4M | 27.7M | 37.6M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.34M | -3.45M | 206K | 4.25M | 2.25M | 5.26M | -3.18M | -15.9M | -14.7M | -16.5M | -14.3M |
| Capital Expenditure | 355K | 712K | 713K | 443K | 605K | 465K | 644K | 1.27M | 1.42M | 4.94M | 5.86M |
| Free Cash Flow | 982K | -4.16M | -506K | 3.81M | 1.65M | 4.79M | -3.82M | -17.1M | -16.1M | -21.4M | 460K |
| Ratios | |||||||||||
| ROE | 16.5% | -2.5% | -1.4% | 5.5% | -6.0% | 1.5% | -4.0% | -36.4% | -48.6% | -151.1% | -104.0% |
| ROA | 8.6% | -1.4% | -0.7% | 2.8% | -2.9% | 0.9% | -2.9% | -22.6% | -23.1% | -37.1% | -33.8% |
| Net Profit Margin | 10.8% | -1.9% | -0.9% | 3.4% | -4.1% | 1.6% | -5.3% | -35.0% | -29.7% | -41.5% | -68.6% |
| Debt to Equity | 0.11x | 0.19x | 0.27x | 0.32x | 0.42x | 0.20x | 0.13x | 0.15x | 0.34x | 1.43x | 1.05x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
EDAP TMS S.A. dividends
EDAP TMS S.A. has not paid dividends in the last 9 fiscal years.
Who owns EDAP TMS S.A.
- Insiders 5.38%
- Institutions 40.32%
- Public & others 54.30%
- Shares outstanding 47.2M
- Free float 34.1M
Top funds holding FOCL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Calamos Timpani Small Cap Growth I | 427K | 0.90% | 0.00% | Aug 2026 |
| Bruce | 415K | 0.88% | 0.00% | Sep 2026 |
| 1290 Essex Small Cap Growth I | 126K | 0.27% | +0.53% | Sep 2026 |
| Russell Inv US Small Cap Equity Y | 38.0K | 0.08% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 24.9K | 0.05% | 0.00% | Aug 2026 |
| Russell Inv Global Small Cap Eq SGAM Rtl | 2.90K | 0.01% | 0.00% | Sep 2026 |
| Russell Inv Gbl Smaller Companies Pl F | 2.02K | 0.00% | 0.00% | Sep 2026 |
| LUX IM Global Medtech HX | 41.00 | 0.00% | 0.00% | Sep 2026 |
Top institutions holding FOCL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Soleus Capital Management, L.P. | 7.31M | 15.48% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 3.34M | 7.07% | -0.25% | Jun 2026 |
| FLAX POND CAPITAL, LLC | 1.53M | 3.23% | +94.74% | Jun 2026 |
| Rock Springs Capital Management LP | 1.39M | 2.94% | +0.58% | Jun 2026 |
| Bruce & Co Inc | 439K | 0.93% | 0.00% | Jun 2026 |
| Parkman Healthcare Partners LLC | 155K | 0.33% | 0.00% | Jun 2026 |
| Essex Investment Management Company, LLC | 146K | 0.31% | 0.00% | Jun 2026 |
| OHE Financial Inc | 135K | 0.29% | 0.00% | Jun 2026 |
| U.S. Bancorp | 123K | 0.26% | +2.94% | Jun 2026 |
| UBS Group AG | 118K | 0.25% | -30.20% | Jun 2026 |
| Sage Mountain Advisors LLC | 100K | 0.21% | 0.00% | Jun 2026 |
| LEONTEQ SECURITIES AG | 95.0K | 0.20% | 0.00% | Jun 2026 |
| Summit Trail Advisors, LLC | 82.3K | 0.17% | -19.54% | Jun 2026 |
| Cetera Investment Advisers | 74.0K | 0.16% | 0.00% | Jun 2026 |
| Commonwealth Equity Services, LLC | 69.2K | 0.15% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 66.2K | 0.14% | 0.00% | Jun 2026 |
| Legato Capital Management LLC | 48.3K | 0.10% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 42.7K | 0.09% | 0.00% | Jun 2026 |
| Schonfeld Strategic Advisors LLC | 41.7K | 0.09% | +61.36% | Jun 2026 |
| Manatuck Hill Partners LLC | 27.6K | 0.06% | 0.00% | Jun 2026 |
EDAP TMS S.A. company profile
- Company name
- EDAP TMS S.A.
- Ticker
- FOCL.US
- Exchange
- USA Stocks
- Listed since
- Aug 1, 1997
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 289
- Fiscal year end
- December
- Address
- Parc dActivites la Poudrette-Lamartine, Vaulx-En-Velin, France, 69120
- Phone
- 33 4 72 15 31 50
- Website
- investor.focalone.com
About EDAP TMS S.A.
EDAP TMS S.A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. It also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. In addition, the company manufactures and markets lithotripter for the treatment of urinary tract stones; and provides disposables, replacement parts, and services for lithotripters; and sells spare parts and disposables, such as electrodes. Further, it markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales channels, and third-party distributors and agents. The company serves academic, public, and private hospitals, as well as clinics. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop clinical workflows combining PSMA PET imaging and Focal One Robotic HIFU for prostate cancer. EDAP TMS S.A. was incorporated in 1979 and is headquartered in Vaulx-en-Velin, France.
EDAP TMS S.A. management
9- Mr. Ryan RhodesCEO & Director · born 1962
- Mr. Kenneth MobeckChief Financial Officer · born 1971
- Mr. Steven AnnenExecutive Vice President of Marketing & Product Management · born 1964
- Mr. Carre EmmanuelChief Operating Officer
- Mr. Francois DietschChief Accounting Officer · born 1976
- Ms. Blandine ConfortHead of Legal Affairs & Investor Relations and Secretary
- Mr. Frederic PechPresident of EDAP TMS France · born 1969
- Mr. Jean-Francois BachelardPresident & Chief Executive Officer of Edaptechnomed Co. Ltd. · born 1964
- Mr. Sanket Shah J.D.General Counsel & Corporate Secretary · born 1983